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Abstracts
Gregory L. Moneta, MD, Section EditorCombination Antiplatelet Therapy for Secondary Stroke Prevention:
Enhanced Efficacy or Double Trouble?
Usman MHU, Notaro LA, Nagarakanti R, et al. Am J Cardiol 2009;103:
1107-12.
Conclusion: Aspirin and clopidogrel combined are associated with more
bleeding than aspirin or clopidogrel alone.
Summary: Aspirin is effective as an antithrombotic agent for secondary
stroke prevention. It reduces the risk of secondary stroke 15% to 20% compared
with placebo (BMJ 1994;308:81-106) but fails to prevent many events; there-
fore, other antithrombotic agents have been investigated for secondary stroke
prevention. All antithrombotic agents, however, carry a bleeding risk, and some
bleeding episodes are fatal; for example, bleeding associated with antithrom-
botic agents for secondary prevention leads to higher mortality in patients with
acute coronary syndromes (Circulation 2006;114:774-82). In this report the
authors sought to compare bleeding risk associated with secondary stroke
prevention regimens for noncardioembolic strokes. They focused on analyzing
recent studies of combinations of antiplatelet agents.
The authors assessed annualized rates of total and major bleeding
events in secondary stroke prevention trials of antithrombotic agents. They
searched Medline for major randomized clinical studies with a follow-up
duration of1 year and identified 13 studies. They used pooled data sets to
compare mean bleeding rates for aspirin (325 mg/d), clopidogrel, anti-
coagulants (warfarin and other vitamin K antagonists), aspirin plus clopi-
dogrel, and aspirin plus extended-release dipyridamole (ER-DP). Total
bleeding occurred at mean rates of 4.8% with aspirin (325 mg/d) alone,
2.9% with clopidogrel alone, 3.6% with aspirin plus ER-DP, 10.1% with
aspirin plus clopidogrel, and 16.8% with anticoagulation. Mean bleeding
occurred at mean rates of 1% with aspirin (325 mg/d) alone, 0.85% with
clopidogrel, 0.93% with aspirin plus ER-DP, 1.7% with aspirin plus clopi-
dogrel, and 2.5% with anticoagulation.
Comment: The 13 studies analyzed in this article included 87,205
patients. The estimated bleeding risks associated with various forms of
pharmacologic secondary stroke prophylaxis are therefore probably accu-
rate. However, reporting of bleeding rates is hampered by lack of a common
classification scheme for bleeding episodes. The main point of this article is
to point out that bleeding rates with combinations of antiplatelet therapies
or anticoagulation, in patients with previous stroke, are really quite signifi-
cant. In all but 1 of the 13 studies analyzed, the mean patient age was 70
years. If one wishes to extrapolate these data to vascular surgical patients,
who are in many cases older than those analyzed here, the likely risk of dual
antiplatelet therapy might be even higher.
Vascular Medicine
Metabolic Syndrome, Inflammation, and Risk of Symptomatic Periph-
eral Artery Disease in Women: A Prospective Study
Conen D, Rexrode KM, Creager MA, et al. Circulation 2009;120:1041-7.
Conclusion: Metabolic syndrome can predict future symptomatic
peripheral arterial disease (PAD) in women, with the risk largely mediated by
inflammation and endothelial activation.
Summary: Metabolic syndrome is a cluster of cardiovascular risk
factors associated with insulin resistance and obesity. Its association with a
moderate increase in coronary artery disease, stroke, and cardiovascular
mortality is well established. The association between metabolic syndrome
and PAD is less clear. One prospective study indicated an increased risk of
PAD associated with metabolic syndrome; however, much of the risk related
to the effect to diabetes alone (Diabetes Care 2007;30:13009-3104). A
second study did not find a significant association between metabolic
syndrome and incident PAD (Atherosclerosis 2009;203:604-9).
High-sensitivity C-reactive protein (hsCRP) is now established as a
predictor of cardiovascular morbidity and mortality and as a marker of
inflammation associated with atherosclerosis. In this study the authors
sought to assess the relationship between metabolic syndrome and inflam-
mation with future symptomatic PAD in a large group of essentially healthy
women. This was a prospective cohort study of 27,111 women free of
baseline cardiovascular disease who were participating in the Women’s
Health Study. During a median cohort follow-up of 13.3 years, participants
were monitored for development of incident symptomatic PAD as defined
by development of intermittent claudication or need for lower extremity
arterial revascularization. Of these, 114 women progressed to this end point.
Cox proportional hazard models were used to compare PAD risk in women
with and without metabolic syndrome. Also investigated were relationships
between metabolic syndrome and inflammation as measured by hsCRP and
soluble intercellular adhesion molecule-1 (ICAM-1).
782In women with metabolic syndrome, there was a 62% increase risk of
future PAD (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.10-
2.38). With risk adjustments, there was an additional 21% risk increase per
additional metabolic syndrome-defining trait (adjusted HR, 1.21; 95% CI,
1.06-1.39). In women with and without metabolic syndrome, median levels
were, respectively, 4.0 vs 1.5 mg/L for hsCRP (P .001) and 1374 vs 333
ng/mL for soluble ICAM-1 (P  .0001). Adding hsCRP and soluble
ICAM-1 to the multivariable model resulted in risk associated with meta-
bolic syndrome being substantially attenuated and no longer significant
(HR, 1.14; 95% CI, 0.75-1.73).
Comment: The study suggests a mechanistic link between metabolic
syndrome and inflammation with the development of PAD in women.
Conclusions are limited by the facts that most of the women were Caucasian
and only symptoms or the need for operation were used to define the
presence of PAD. Clearly, many asymptomatic patients with PAD could have
been missed. Nevertheless, symptomatic PAD is certainly an important
clinical end point, and the study does suggest mechanistic links between risk
factor clustering and onset of PAD in woman.
Outcome Following Endovascular vs. Open Repair of Abdominal
Aortic Aneurysm: A Randomized Trial
Lederle FA, Freischlag JA, Kyriakides TC, and the Open vs. Endovascular
Repair (OVER) Veterans Affairs Cooperative Study Group. JAMA 2009;
302:1535-42.
Conclusion: Perioperative mortality is lower for endovascular than
open AAA repair. There is no significant difference in all cause-mortality at 2
years.
Summary: Previous randomized trials of open vs endovascular aneu-
rysm repair have shown reduced perioperative mortality, hospital stay, and
intensive care unit days in the endovascularly treated patients. In random-
ized trials conducted in Europe, at 2 years the early survival advantage of the
endovascular patients was lost, while the relative effects of endovascular and
open repair on quality of life and erectile function remain unclear. This study
was conducted in 881 veterans aged 49 years drawn from 42 Department
of Veterans Affairs Medical Centers. To be eligible for the trial, the patient
had to have had an abdominal aortic aneurysm (AAA) 5 cm or an AAA
4.5 cm with rapid enlargement or secular morphology. Iliac dilatation was
restricted to3 cm. The current report is a planned interim report of 2-year
outcomes of an ongoing 9-year trial. This report describes the period from
October 15, 2002, to October 15, 2008. There were 444 patients random-
ized to elective endovascular repair and 437 to open repair. The primary
outcome measures included procedure failure, secondary therapeutic proce-
dures, length of stay, erectile dysfunction, mortality, major morbidity, and
quality of life as assessed by the Short Form 36Health Survey and EuroQOL
questionnaires.
There were no significant differences between the demographics of the
two patient groups with the exception of greater prevalence of aspirin use in
the open vs endovascular cohort. Mean follow-up was 1.8 years. Before 2
years, 80% of patients (n  710) had completed follow-up or had died.
Perioperative mortality was higher in the open vs endovascular patients,
although mortality was low in both groups (0.2% vs 2.3%; P .006). At 30
days or during hospitalization, mortality was 0.5% in the endovascular group
vs 3% in the open group (P .004). Mortality did not vary with diameter of
the AAA.
At 2 years, there was no significant difference in all-cause mortality in
the endovascular vs open groups (7% vs 9.8%; hazard ratio, 0.7; 95%
confidence interval, 0.4-1.1; P  .13). After the perioperative period,
mortality was similar in the two groups (6.1% vs 6.6%). There were four late
aneurysm-related deaths in the endovascular group and no late aneurysm-
related deaths in the open group. There were no significant differences in
mortality in any prespecified subgroups for analysis, including coronary
artery disease (P .06). A trend was noted for increasedmortality in patients
treated with AneurRx grafts vs those treated with Zenith or Excluder grafts,
but this did not reach statistical significance. The groups did not differ
significantly in health-related quality of life or erectile function during the 2
years of follow-up. There were no differences in observed secondary proce-
dures in the two groups, with 61 secondary therapeutic procedures in the
endovascular group, of which 42 were catheter-based procedures. There
were 55 secondary procedures in the open group that included 24 incisional
hernia repairs.
Comment: Virtually all the Department of Veterans Affairs hospitals
that participated in this study were university affiliated. Therefore, the
exemplary mortality rates with both open and endovascular repairs may not
be generalized to the United States population. Nevertheless, it is clear it is
